TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ

Patent Applications and Registrations

Patent applications and USPTO patent grants for TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ.The latest application filed is for "therapeutic rna for ovarian cancer".

Company Profile

6.11.15

TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ - Mainz DE
TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz - N/A

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Therapeutic Rna For Ovarian Cancer App 20220257631 - SAHIN; Ugur ; et al.	2022-08-18
Therapy involving antibodies against Claudin 18.2 for treatment of cancer Grant 11,395,852 - Sahin , et al. July 26, 2	2022-07-26
Treatment Involving Interleukin-2 (il2) And Interferon (ifn) App 20220143144 - SAHIN; Ugur ; et al.	2022-05-12
Antibodies useful in cancer diagnosis Grant 11,279,757 - Mitnacht-Kraus , et al. March 22, 2	2022-03-22
Antigen Receptors And Uses Thereof App 20220033461 - VOSS; Ralf Holger ; et al.	2022-02-03
RNA replicon for versatile and efficient gene expression Grant 11,168,337 - Beissert , et al. November 9, 2	2021-11-09
Use Of Rna For Reprogramming Somatic Cells App 20210324341 - Sahin; Ugur ; et al.	2021-10-21
Methods And Compositions For Prediction Of Therapeutic Efficacy Of Cancer Treatments And Cancer Prognosis App 20210324472 - Sahin; Ugur ; et al.	2021-10-21
IL2 Agonists App 20210292386 - Sahin; Ugur ; et al.	2021-09-23
Individualized Vaccines for Cancer App 20210290746 - Sahin; Ugur ; et al.	2021-09-23
Lipid particle formulations for delivery of RNA and water-soluble therapeutically effective compounds to a target cell Grant 11,045,418 - Hefesha , et al. June 29, 2	2021-06-29
Use of RNA for reprogramming somatic cells Grant 11,008,550 - Sahin , et al. May 18, 2	2021-05-18
Treatment Using Cytokine Encoding Rna App 20210113606 - Sahin; Ugur ; et al.	2021-04-22
Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer Grant 10,946,069 - Sahin , et al. March 16, 2	2021-03-16
Formulation For Administration Of Rna App 20210023100 - Sahin; Ugur ; et al.	2021-01-28
Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer App 20200390887 - Sahin; Ugur ; et al.	2020-12-17
Diagnosis And Therapy Of Cancer Involving Cancer Stem Cells App 20200385460 - Sahin; Ugur ; et al.	2020-12-10
Enhancing The Effect Of Car-engineered T Cells By Means Of Nucleic Acid Vaccination App 20200360438 - SAHIN; Ugur ; et al.	2020-11-19
Nucleic acid molecules encoding cytokine fusion proteins comprising tumor necrosis factor (TNF) superfamily ligands Grant 10,808,019 - Sahin , et al. October 20, 2	2020-10-20
Particles comprising a shell with RNA Grant 10,576,146 - Sahin , et al.	2020-03-03
Antigen Receptors And Uses Thereof App 20200063101 - VOSS; Ralf Holger ; et al.	2020-02-27
Peptide Mimotopes Of Claudin 18.2 And Uses Thereof App 20200031898 - Sahin; Ugur ; et al.	2020-01-30
Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer App 20190298803 - Sahin; Ugur ; et al.	2019-10-03
Individualized vaccines for cancer Grant 10,155,031 - Sahin , et al. Dec	2018-12-18
Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer Grant 10,022,444 - Sahin , et al. July 17, 2	2018-07-17
Antibodies against Claudin 18.2 useful in cancer diagnosis Grant 9,512,232 - Sahin , et al. December 6, 2	2016-12-06

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.